Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
The role of antiangiogenesis therapy: Bevacizumab and beyond
Clinical and Translational Oncology, 06/30/09
Cortes-Funes H et al. - Clinical data from trials of anti-VEGF agents in this group of tumours are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in those tumour types.
Related Articles
Issues in postmenopausal hormone therapy: A 3-part CME newsletter series Counseling patients about bioidentical hormone preparations
Sexuality, Reproduction & Menopause, 11/13/09
Relevance Score: 47%
Issues in postmenopausal hormone therapy: depression, endometrial health, and discontinuation
Sexuality, Reproduction & Menopause, 10/09/09
Relevance Score: 47%
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Relevance Score: 46%
A New Era in Iron Chelation Therapy: The Design of Optimal, Individually Adjusted Iron Chelation Therapies for the Complete Removal of Iron Overload in Thalassemia and other Chronically Transfused Patients
Hemoglobin, 10/23/09
Relevance Score: 46%
Sonodynamic and Photodynamic Therapy in Advanced Breast Carcinoma: A Report of 3 Cases
Integrative Cancer Therapies, 10/13/09
Relevance Score: 46%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


